Xiao Hu

Xiao Hu


Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 October 2013 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
JCJiekai Chen
Jiekai Chen
LGLin Guo
Lin Guo
LZLei Zhang
Lei Zhang
HWHaoyu Wu
Haoyu Wu
JYJiaqi Yang
Jiaqi Yang
DPDuanqing Pei
Duanqing Pei

1 April 2014 in Cell Stem Cell
Verified
Journal Article
Closed access
XHXiao Hu
Xiao Hu
LZLei Zhang
Lei Zhang
SMShi-Qing Mao
Shi-Qing Mao
ZLZheng Li
Zheng Li
JCJiekai Chen
Jiekai Chen
GXGuo-Liang Xu
Guo-Liang Xu

3 December 2024 in Cell Proliferation
Verified
Journal Article
Open access
YZYiming Zhang
Yiming Zhang
JLJing Li
Jing Li
JLJiane Liu
Jiane Liu
YGYan Gao
Yan Gao
KLKehan Li
Kehan Li
ZWZheng Wang
Zheng Wang
Osteoarthritis (OA) is a chronic, degenerative joint disease primarily characterised by damage to the articular cartilage, synovitis and persistent pain, and has become one of the most common diseases worldwide. In OA cartilage, various forms of cell death have been identified, including apoptosis, necroptosis and autophagic cell death. Ever‐growing observations indicate that ferroptosis, a newly‐discovered iron‐dependent form of regulated cell death, is detrimental to OA occurrence and progression. In this review, we first analyse the pathogenetic mechanisms of OA by which iron overload, inflammatory response and mechanical stress contribute to ferroptosis. We then discuss how ferroptosis exacerbates OA progression, focusing on its impact on chondrocyte viability, synoviocyte populations and extracellular matrix integrity. Finally, we highlight several potential therapeutic strategies targeting ferroptosis that could be explored for the treatment of OA.

12 April 2019 in Nature Communications
Verified
Journal Article
Open access
PDF file
XHXiao Hu
Xiao Hu
ZLZongzhi Z. Liu
Zongzhi Z. Liu
XCXinyue Chen
Xinyue Chen
VSVincent P. Schulz
Vincent P. Schulz
AKAbhishek Kumar
Abhishek Kumar
SGShangqin Guo
Shangqin Guo
Actin cytoskeleton is well-known for providing structural/mechanical support, but whether and how it regulates chromatin and cell fate reprogramming is far less clear. Here, we report that MKL1, the key transcriptional co-activator of many actin cytoskeletal genes, regulates genomic accessibility and cell fate reprogramming. The MKL1-actin pathway weakens during somatic cell reprogramming by pluripotency transcription factors. Cells that reprogram efficiently display low endogenous MKL1 and inhibition of actin polymerization promotes mature pluripotency activation. Sustained MKL1 expression at a level seen in typical fibroblasts yields excessive actin cytoskeleton, decreases nuclear volume and reduces global chromatin accessibility, stalling cells on their trajectory toward mature pluripotency. In addition, the MKL1-actin imposed block of pluripotency can be bypassed, at least partially, when the Sun2-containing linker of the nucleoskeleton and cytoskeleton (LINC) complex is inhibited. Thus, we unveil a previously unappreciated aspect of control on chromatin and cell fate reprogramming exerted by the MKL1-actin pathway.

27 June 2017 in Hepatology
Verified
Journal Article
Closed access
PDF file
JLJunlai Liu
Junlai Liu
XHXiao Hu
Xiao Hu
JCJie Chen
Jie Chen
XLXinqi Li
Xinqi Li
LWLu Wang
Lu Wang
PHPengyu Huang
Pengyu Huang

19 October 2020 in Stem Cells
Verified
Journal Article
Open access
PDF file
XHXiao Hu
Xiao Hu
QWQiao Wu
Qiao Wu
JZJian Zhang
Jian Zhang
JKJonghun Kim
Jonghun Kim
XCXinyue Chen
Xinyue Chen
SGShangqin Guo
Shangqin Guo
There is wide variability in the propensity of somatic cells to reprogram into pluripotency in response to the Yamanaka factors. How to segregate these variabilities to enrich for cells of specific traits that reprogram efficiently remains challenging. Here we report that the variability in reprogramming propensity is associated with the activity of the MKL1/SRF transcription factor and concurs with small cell size as well as rapid cell cycle. Reprogramming progressive cells can be prospectively identified by their low activity of a widely used synthetic promoter, CAG. CAGlow cells arise and expand during cell cycle acceleration in the early reprogramming culture of both mouse and human fibroblasts. Our work illustrates a molecular scenario underlying the distinct reprogramming propensities and demonstrates a convenient practical approach for their enrichment.